EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome

Amee Revana, Rakesh Bhattacharjee, Jennifer L Miller, Aaron Chidekel, Priya Khanna, Sarayu Ratnam, Grant Runyan, Eric Bauer, Krystle Davis Rapchak, David Seiden, Kumar Budur, Jeffrey M Dayno

Journal of Clinical Sleep Medicine · 2025

DOI: 10.5664/jcsm.11800 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Sleep Medicine, 2025. Verfasst von Amee Revana und 11 weiteren Autor:innen. Beteiligte Einrichtung: Baylor College of Medicine, Texas Children's Hospital, Houston, Texas. Hauptthemen laut MEDLINE: Disorders of Excessive Somnolence, Piperidines, Prader-Willi Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY OBJECTIVES: The majority of patients with Prader-Willi syndrome experience excessive daytime sleepiness (EDS). This study evaluated the effects of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist that promotes wakefulness, in patients with Prader-Willi syndrome and EDS. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, proof-of-concept study, patients ages 6-65 years with a confirmed diagnosis of Prader-Willi syndrome with EDS were randomized 1:1:1 to receive lower-dose pitolisant (children/adolescents/adults, 8.9/13.35/17.8 mg), higher-dose pitolisant (children/adolescents/adults, 17.8/26.7/35.6 mg), or matching placebo for 11 weeks (3-week titration/8-week maintenance). The primary endpoint was change from baseline to week 11 in Epworth Sleepiness Scale for Children and Adolescents (parent/caregiver version) score. Other measures included the Caregiver Global Impression of Severity for EDS, Aberrant Behavior Checklist-Community, second edition, and Hyperphagia Questionnaire for Clinical Trials. RESULTS: Of 65 patients randomized and treated, 59 (90.8%) completed the double-blind phase. Least-squares (LS) mean improvement from baseline to week 11 in Epworth Sleepiness Scale for Children and Adolescents score was greater for higher-dose pitolisant (-5.0) vs placebo (-3.9; LS mean [standard error] difference, -1.1 [1.52]), but not for lower-dose pitolisant (-3.5) vs placebo (LS mean [standard error] difference, 0.5 [1.6]). The largest effect of pitolisant was seen in children (ages 6 to < 12 years; LS mean [standard error] difference for higher-dose pitolisant vs placebo, -3.5 [1.90]). Improvements were observed across other measures, especially in the higher-dose pitolisant group, including LS mean (standard error) change of -5.5 (1.2) on the irritability domain of the Aberrant Behavior Checklist-Community, second edition, and -3.1 (1.0) on the Hyperphagia Questionnaire for Clinical Trials. The most common adverse events in pitolisant-treated patients (doses pooled) were anxiety, irritability, and headache (11.9% each), consistent with the known safety profile of pitolisant. CONCLUSIONS: Results of this proof-of-concept study support further evaluation of pitolisant in patients with Prader-Willi syndrome and EDS. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension; URL: https://clinicaltrials.gov/study/NCT04257929; Identifier: NCT04257929. CITATION: Revana A, Bhattacharjee R, Miller JL, et al. A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome. J Clin Sleep Med. 2025;21(11):1893-1902.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disorders of Excessive SomnolencePiperidinesPrader-Willi SyndromeAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugDouble-Blind MethodProof of Concept StudyTreatment Outcome

Stichwörter der Autor:innen

H3 histamine receptor antagonistsbehavioral symptomsexcessive daytime sleepinesshistamine H3 receptorproof-of-concept study

Substanzen

Piperidinespitolisant

Autor:innen und Institutionen

  • Baylor College of Medicine, Texas Children's Hospital, Houston, Texas.
  • Rady Children's Hospital, University of California San Diego, San Diego, California.
  • University of Florida Health Shands Hospital, Gainesville, Florida.
  • Nemours Children's Health, Wilmington, Delaware.
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
  • Harmony Biosciences, Plymouth Meeting, Pennsylvania.

Zitieren

APA

Revana, A., Bhattacharjee, R., Miller, J. L., Chidekel, A., Khanna, P., Ratnam, S., Runyan, G., Bauer, E., Davis Rapchak, K., Seiden, D., Budur, K., & Dayno, J. M. (2025). A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.11800

Vancouver

Revana A, Bhattacharjee R, Miller JL, Chidekel A, Khanna P, Ratnam S, et al. A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome. Journal of Clinical Sleep Medicine. 2025. doi:10.5664/jcsm.11800

BibTeX
@article{Revana2025,
  author = {Revana, Amee and Bhattacharjee, Rakesh and Miller, Jennifer L and Chidekel, Aaron and Khanna, Priya and Ratnam, Sarayu and Runyan, Grant and Bauer, Eric and Davis Rapchak, Krystle and Seiden, David and Budur, Kumar and Dayno, Jeffrey M},
  title = {A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome},
  journal = {Journal of Clinical Sleep Medicine},
  year = {2025},
  doi = {10.5664/jcsm.11800}
}
Kostenlos starten →